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Transcriptional regulation by the ubiquitous human POU homeo domain protein Oct-1 and the related B-cell 
protein Oct-2 is a model for understanding how proteins that recognize the same regulatory site elicit different 
programs of gene transcription. Here, we describe a mechanism for differential promoter activation whereby 
only Oct-l, through selective corecruitment with the herpesvirus trans-activator VPI6, acquires the ability to 
stimulate transcription from a TAATGARAT-containing site that responds to neither Oct-1 nor Oct-2 alone. 
To measure differential in vivo activation by human Oct-1 and Oct-2 in response to VP16, we have developed 
a transient assay in murine NIH-3T3 cells. Surprisingly, murine Oct-1 associates with VP16 much less 
effectively than its human counterpart, most likely because the murine Oct-1 homeo domain differs at four 
positions from the human Oct-1 homeo domain. The murine cell transient assay shows directly that human 
Oct-l, but not human Oct-2, can respond to VP16 in vivo. The Oct-1 DNA-binding POU domain is sufficient 
and the Oct-1 homeo domain is critical for this response, because an Oct-1 POU domain containing the Oct-2 
homeo domain fails to respond to the VP16-induced positive control of transcription. Thus, by selective 
homeo domain interaction and corecruitment o an otherwise silent regulatory element, VP16 expands the 
repertoire of sites responsive to Oct-1 without affecting the activity of its close relative Oct-2. 
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A perplexity of eukaryotic transcriptional regulation is 
the ability of proteins with the same inherent DNA- 
binding specificity to direct distinct patterns of gene ex- 
pression. This apparent paradox has been underscored by 
studies of Drosophila development, where numerous ho- 
meo domain proteins with highly similar DNA-binding 
properties participate in unique programs of transcrip- 
tional regulation. In many cases, the homeo domain it- 
self confers the specificity of transcriptional regulation 
by mechanisms that are poorly understood (see Hayashi 
and Scott 1990). 
The mammalian POU homeo domain proteins Oct-1 
and Oct-2 serve as models for resolving these mecha- 
nisms. Via their homeo domain-containing POU do- 
mains, both proteins recognize the same DNA se- 
quences, including the octamer motif ATGCAAAT 
(Staudt et al. 1986; Clerc et al. 1988; Sturm et al. 1988; 
Aurora and Herr 1992). One mechanism by which they 
can differentially regulate gene expression is through 
promoter-selective activation domains, which stimulate 
3Present address: University of Massachusetts Medical Center, Program 
in Molecular Medicine, Worcester, Massachusetts 01613 USA. 
transcription from specific octamer motif-containing 
promoters (Tanaka et al. 1988; Tanaka et al. 1992). Pre- 
vious in vivo studies have demonstrated that, by this 
mechanism, Oct-1 activates the human U2 small nu- 
clear RNA (snRNA) promoter more effectively than 
Oct-2 does (Tanaka et al. 1992), and Oct-2 activates the 
human ~-globin promoter, an mRNA-type promoter, 
more effectively than Oct-1 does (Tanaka and Herr 1990; 
Kemler et al. 1991). Oct-l, however, appears to acquire 
Oct-2-1ike mRNA promoter activation properties by as- 
sociation with the herpes simplex virus (HSV) trans-ac- 
tivator VP16 (also called Vmw65 and ~TIF), which con- 
tains a potent acidic mRNA-type promoter activation 
domain (for review, see Goding and O'Hare 1989; Herr 
1992; Thompson and McKnight 1992). 
During a lytic infection, the virion protein VP16 ini- 
tiates a developmental program of HSV gene expression 
by associating with Oct-1 in a multiprotein-DNA com- 
plex. Efficient formation of this VP16-induced complex 
depends on a second, less well-characterized, host cell 
factor called HCF (also called C1, CCF, and VCAF) (Ger- 
ster and Roeder 1988; Kristie et al. 1989; Katan et al. 
1990; Xiao and Capone 1990; Stern and Herr 1991) and is 
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directed by the cis-regulatory target of VP 16, the TAAT- 
GARAT [R = purine) motif {McKnight et al. 1987; 
O'Hare and Goding 1988; Preston et al. 1988). Two forms 
of the TAATGARAT element exist in the promoters of 
the HSV immediate arly genes. One form, referred to 
here as {OCTA + )TAATGARAT, is characterized by an 
overlapping octamer motif, which binds Oct-1 and 
Oct-2 (Gerster and Roeder 1988; O'Hare and Goding 
1988). The second form of the TAATGARAT motif, 
called [OCTA-)TAATGARAT, lacks an overlapping oc- 
tamer motif. On such a site, Oct-1 and Oct-2 recognize 
the TAATGARAT motif as a degenerate octamer se- 
quence and bind with weak affinity {Baummker et al. 
1988; apRhys et al. 1989; Aurora and Herr 1992). 
Unlike Oct-l, Oct-2 does not associate effectively 
with VP16 (Gerster and Roeder 1988}. This differential 
interaction does not depend on the presence of HCF 
[Stem and Herr 1991; Pomerantz et al. 1992) and results 
from amino acid differences on the surfaces of the Oct-1 
and Oct-2 homeo domains that are thought o be acces- 
sible for protein contacts when the homeo domains are 
bound to DNA {Stern et al. 1989; Lai et al. 1992; Pomer- 
antz et al. 1992). Thus, the selective association of VP16 
with Oct-1 demonstrates how a regulatory cofactor can 
discriminate between homeo domains, even those bound 
to the same DNA site. 
Although VP16 associates selectively with Oct-1, the 
mRNA promoter activation properties of Oct-1 and 
Oct-2 in the presence or absence of VP16 have been an- 
alyzed on an octamer motif-containing cis-regulatory 
site that is active in the presence of either Oct-2 or a 
combination of Oct-1 and VP16 {Tanaka et al. 1988). 
Thus, in this case, the selective association of Oct-1 with 
VP16 does not result in the activation of different pro- 
moters by Oct-1 and Oct-2. 
We show here that, in our assays, an (OCTA-) 
TAATGARAT element does not respond effectively to 
either Oct-1 or Oct-2 in the absence of VP16. Oct-l, how- 
ever, acquires new and distinctive properties not shared 
with Oct-2 by activating transcription on this site in the 
presence of VP16. The response to Oct-1 correlates with 
the ability of VP 16 and Oct-1 to recruit each other to this 
type of TAATGARAT element. This selective corecruit- 
ment reveals a second mechanism whereby proteins 
with the same inherent DNA-binding specificity can di- 
rect distinct patterns of gene expression, i  this case 
through discriminating protein interaction with the 
DNA-binding domain. 
Resu l ts  
To compare the activities of Oct-1 and Oct-2 on the 
low-affinity {OCTA-JTAATGARAT site, we used an 
[OCTA-}TAATGARAT site from the bidirectional HSV 
IE3 [ICP4} and IE4/5 immediate arly promoter charac- 
terized previously by Preston and colleagues (Preston et 
al. 1988). As a positive control for Oct-1 and Oct-2 ac- 
tivity, we measured the activity of an octamer motif 
originating from the human histone H2B promoter. Fig- 
ure 1A shows the sequence of the two sites, along with 
double point mutations used to inactivate ach site. As 
indicated in Figure 1A by the underlying broken bracket, 
the H2B octamer motif resembles an {OCTA + }TAATG- 
ARAT site because of a 6- of 9-base match to the TAAT- 
GARAT sequence; consistent with this sequence simi- 
larity, this octamer motif, together with a critical C res- 
idue provided by the XhoI l inker sequence (CTC; boxed 
in Fig. 1A), binds to VP16 (see below} and responds to 
VP16 in vivo {data not shown). 
To measure transcriptional activity of the wild-type 
and mutant octamer and {OCTA-)TAATGARAT sites 
in response to Oct-1 and Oct-2 in transient expression 
assays, we designed the reporter plasmid illustrated in 
Figure lB. The plasmid contains two divergently ori- 
Figure 1. [A) Wild-type and mutant sequences of the octamer 
(top) and (OCTA-ITAATGARAT [bottomJ elements used in 
this study. Brackets above each sequence define th  location of 
each motif, and boxed residues represent XboI recognition se- 
quences used to separate the individual sites in the six tandem 
copy constructs. Vertical arrows beneath each wild-type se- 
quence (WT) indicate mutated bases within the mutant forms of 
each site {Mut.). A bracket marking asequence overlapping the 
octamer motif highlights similarity to a TAATGARAT motif (a 
6- of 9-base match} with X's designating the differences. (B) A 
schematic representation f the pU2/[~ reporter plasmid used 
for the in vivo studies. The pUC119-based plasmid contains two 
transcription units, U2 {hatched} and ~-globin [solidi, driven by 
divergent promoters oriented as indicated by the wavy arrows. 
Small rectangles and arrows illustrate the array of six tandem 
sequence lements generated for each c/s-regulatory site and 
inserted between the two promoters. 
GENES & DEVELOPMENT 73 
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
Cleary et al. 
ented reporter genes, one driven by the Oct-1-responsive 
U2 snRNA promoter and the other driven by the Oct-2- 
responsive ~-globin mRNA promoter. To test the tran- 
scriptional response of each site, we generated synthetic 
enhancers comprised of six tandem copies of each wild- 
type and mutant site and inserted each synthetic en- 
hancer individually between the two promoters. This 
double-promoter construct allowed us not only to mea- 
sure U2 snRNA and 13-globin mRNA promoter activa- 
tion in different cell types but also to evaluate their re- 
sponsiveness to VP16. To assay promoter activity, we 
measured levels of mRNA synthesis by RNase protec- 
tion and compared these levels to those from a cotrans- 
fected internal reference plasmid containing the human 
oL-globin transcription unit. 
Oct-1 and Oct-2 fail to activate the (OCTA-) 
TAA TGARA T element in the absence of VP16 
Figure 2 shows the response of the U2 snRNA and the 
f~-globin mRNA promoters in HeLa cells, which contain 
Oct-l, to the octamer and (OCTA-)TAATGARAT sites 
along with the response of the 13-globin mRNA promoter 
in murine NS-1 B cells, which contain both Oct-1 and 
Oct-2. As positive and negative controls for activation of 
both promoters in both cell types, we used wild-type 
(octa + sph + ) and mutant (octa- sph- ) copies of a bipar- 
tite SV40 enhancer element containing an octamer motif 
overlapping tandem 9-bp sph motifs. The octamer motif 
can activate the U2 snRNA promoter in HeLa cells and 
the U2 and f~-globin promoters in B cells, whereas the 
tandem sph motifs can activate the f3-globin promoter in 
HeLa cells (Tanaka et al. 1988). By virtue of the com- 
bined activities of these motifs, the wild-type element is 
active in each assay (Fig. 2A, lanes 2,8; Fig. 2B, lane 2), 
whereas the mutant version is inactive (Fig. 2A, lanes 
1,7; Fig. 2B, lane 1). 
In HeLa cells (Fig. 2A), although the wild-type (U2; 
lane 3) but not mutant (lane 4) octamer sequence ffec- 
tively activates the U2 snRNA promoter, the wild-type 
and mutant (OCTA-)TAATGARAT sequences fail to do 
so (lanes 5,6). Consistent with the inability of a wild- 
type octamer motif to activate the minimal f~-globin pro- 
moter effectively in HeLa cells (Tanaka et al. 1988), 
when the same samples probed for U2 snRNA promoter 
activity in lanes 1-6 were probed for ~-globin mRNA 
transcripts as shown in lanes 7-12, neither the octamer 
nor the (OCTA-)TAATGARAT element activated tran- 
scription (~; lanes 9,11). In contrast, in the B-cell line 
(Fig. 2B), the 13-globin promoter esponds to tandem cop- 
ies of the wild-type (lane 3) but not mutant (lane 4) oc- 
tamer motif but, as in the case of the U2 promoter in 
HeLa cells, fails to respond to the wild-type and mutant 
(OCTA-)TAATGARAT site (lanes 5,6). This result was 
also obtained in two human B cell lines, Namalwa and 
BJA-B (data not shown), but their transfection efficien- 
cies were greatly reduced from that of the murine NS-1 
cell line described above. 
Thus, in two instances--the U2 snRNA promoter in 
HeLa cells and the ~-globin mRNA promoter in B cells-- 
the (OCTA-)TAATGARAT site fails to activate an oc- 
tamer motif-responsive promoter. This unequivocal re- 
sult provides the basis for the mode of differential regu- 
lation of gene expression by Oct-1 and Oct-2 described 
here, because this (OCTA-)TAATGARAT element is 
known to activate an mRNA-type promoter in response 
to VP16 in vivo (Preston et al. 1988; see also Triezenberg 
et al. 1988b), and VP16 is known to associate ffectively 
with Oct-1 but not Oct-2 in vitro (Gerster and Roeder 
1988; Kristie et al. 1989; Stem et al. 1989). We present 
evidence below that by selective corecruitment Oct-1 
and VP16 can uniquely activate transcription from the 
low-affinity (OCTA-)TAATGARAT site. 
Figure 2. The HSV (OCTA-)TAATGARAT element fails to 
activate octamer-responsive promoters in the absence of VP 16. 
(A) Expression from the U2 and 13-globin promoter constructs in 
HeLa cells. The octa-sph- {lanes 1,7) and octa + sph + (lanes 2,8) 
sites served as negative and positive activation controls, respec- 
tively. The activity of both promoters with the wild-type (lanes 
3, 9) and mutant (lanes 4,10) H2B octamer site, and the wild-type 
{lanes 5,11) and mutant (lanes 6,12)(OCTA-)TAATGARAT 
site is shown. (PROM.) Promoter activity assayed; (RT) 
readthrough transcripts; (U2) correctly initiated U2 promoter- 
driven transcripts; {13) correctly initiated ~-globin promoter- 
driven transcripts; (a) internal human a-globin control. (B) An 
analogous assay to that described in A, except NS- 1 B cells were 
used and only 13-globin RNA was measured. All lanes and ab- 
breviations are as described in A. 
The (OCTA-)TAATGARAT element can activate 
both the [3-globin and U2 promoters in the presence 
of VP16 
Figure 3 shows that the (OCTA-)TAATGARAT ele- 
ment can activate both the 13-globin mRNA and the U2 
snRNA promoters in the presence of VP 16. Activation of 
mRNA promoters by VP16 depends on a potent carboxy- 
terminal acidic activation domain of VP16 (Triezenberg 
et al. 1988a; Greaves and O'Hare 1989). We used our 
double-promoter reporter constructs to assay the mRNA 
and snRNA promoter esponses of the (OCTA-)TAAT- 
GARAT site to VP16 and two mutant forms of VP16: 
One lacks the carboxy-terminal ctivation domain (AC), 
and the other both lacks the carboxy-terminal domain 
and contains a4-amino-acid insertion (inl4; also referred 
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Figure 3. The HSV (OCTA-)TAATGARAT site activates 
J3-globin mRNA and U2 snRNA gene transcription in the pres- 
ence of VP16. The response of wild-type [(WT) lanes 1,3,5,7,9, 
11] and mutant [(Mut.) lanes 2,4,6,8,10,12] (OCTA-)TAATGA- 
RAT (TAAT} sites was assayed in the presence of wild-type 
VP16 [(WT) lanes 1,2,7,8] and VP16 mutants AC (lanes 3,4,9,10) 
and AC-inl4 {lanes 5,6,11,12) for ~-globin mRNA {left) and U2 
snRNA {right) gene transcription. Other abbreviations re as in 
Fig. 2. The same RNA samples were used to probe for 13-globin 
and U2 RNA (data not shown). 
to as RIIi in Stem and Herr 1991}, which prevents VP16 
association with Oct-1 (Ace et al. 1988; Stern and Herr 
1991). Immunoblot analysis revealed that wild-type 
VP16 was expressed in transient assays at a lower level 
than the two mutant forms, which were expressed at 
similar levels. 
As shown in Figure 3, in the presence of wild-type 
VP16, the otherwise silent (OCTA-)TAATGARAT site 
can readily activate not only the ~-globin promoter (lane 
1) but also the U2 snRNA promoter (lane 7) in HeLa 
cells. Activation of both promoters is disrupted by the 
double point mutation in the (OCTA-)TAATGARAT 
site (lanes 2,8) and by the combined AC and inl4 muta- 
tion in VP16 (lanes 5,11). Consistent with previous re- 
sults, activation of the f~-globin promoter is also lost 
when the carboxy-terminal activation domain of VP16 is 
removed {lane 3). 
Because the U2 snRNA promoter does not respond to 
the yeast acidic activator GAL4 (Tanaka et al. 1988) nor 
to a fusion protein containing the GAL4 DNA-binding 
domain and the carboxy-terminal acidic VP16 activation 
domain (G. Das and W. Herr, unpubl.), the VP16 activa- 
tion domain is not expected to play a role in activation of 
the U2 promoter. Consistent with this hypothesis, the 
U2 promoter with the wild-type (lane 9), but not the 
mutant (lane 10)(OCTA-)TAATGARAT element still 
responds to VP16AC, albeit three- to fourfold less effec- 
tively, despite the absence of the carboxy-terminal acti- 
vation domain. Therefore, it is likely that VP 16 does not 
provide an activation domain but, instead activates the 
U2 promoter by inducing complex formation with Oct-1 
Activation through Oct-1/VP16 corecruitment 
on the (OCTA-)TAATGARAT element and thus allow- 
ing the snRNA activation domains in Oct-1 to activate 
transcription of this promoter. We do not know the rea- 
sons for the reduced efficiency with which the U2 pro- 
moter is activated by the carboxy-terminaUy truncated 
VP 16 protein, but it may be the result of its higher level 
of expression or an alteration of the protein structure. 
Oct-1 but not Oct-2 is corecruited with VP16 
to the (OCTA- )TAATGARAT element 
There are two nonmutually exclusive models that can 
explain how VP16 activates the U2 promoter from the 
(OCTA-)TAATGARAT element by inducing complex 
formation with Oct-1. The first model posits that Oct-1 
is bound to the (OCTA-)TAATGARAT site in vivo but 
is not in a functional state unless also bound to VP16. 
The second model postulates that in the absence but not 
in the presence of VP16, the Oct-1 occupancy of the 
(OCTA-)TAATGARAT site in vivo is not high enough 
to stimulate transcription well. Consistent with the 
model that VP 16 increases the occupancy of Oct-1 on the 
(OCTA-)TAATGARAT site, in an electrophoretic mo- 
bility retardation assay using HeLa nuclear extract, the 
(OCTA-}TAATGARAT site can form more Oct-l-con- 
taining VP16-induced complex in the presence of VP16 
than the complex containing only Oct-1 in the absence 
of VP16 {Preston et al. 1988). To extend this observation, 
we used more defined components and a DNase I pro- 
tection assay to measure the effects of VP16 on occu- 
pancy of the (OCTA-)TAATGARAT site by Oct-1 and 
Oct-2 in Solution. 
We used the DNA probe illustrated in Figure 4 {bot- 
tom) to assay the ability of Oct-1 or Oct-2 to bind simul- 
taneously to the H2B octamer and (OCTA-)TAATGAR- 
AT sites in the presence and absence of VP16. The oc- 
tamer site serves as a positive control not only for Oct-1 
and Oct-2 binding on their own but also for their binding 
in association with VP16, because it resembles an 
(OCTA+)TAATGARAT site {see Fig. 1A), on which 
VP16 extends the Oct-1 protection pattern (Kristie et al. 
1989). We expressed and purified from Escherichia coli 
the Oct-1 and Oct-2 POU domains as well as a protein 
A-VP16 fusion protein (Werstuck and Capone 1989b). 
HCF was provided by a partially purified HeLa cell-de- 
rived fraction devoid of Oct-1 activity. 
As shown in Figure 4A (lanes 1,2), we first adjusted the 
concentration of Oct-1 such that protection of the 
(OCTA-)TAATGARAT site is just detectable. At this 
concentration, the higher affinity octamer site is fully 
protected. At higher concentrations of Oct-1 (~8-fold), 
the partially protected r sidues at the (OCTA-}TAATG- 
ARAT site in lane 2 are completely protected (data not 
shown). Alone, the concentration of VP16 used in this 
assay has no effect on either site (cf. lanes 1 and 6), and 
the HCY-containing fraction has no effect on either the 
Oct-1 {cf. lanes 2 and 3} or VP16 {lanes 5 and 6} protection 
patterns. In contrast, the combination of all three fac- 
tors, Oct-l, VP16, and HCF, extends the protection on 
the octamer site and induces a nearly complete protec- 
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Figure 4. Oct-1 but not Oct-2 is corecruited with VP16 to the 
(OCTA-)TAATGARAT element. A probe (bottom) containing 
the (OCTA-)TAATGARAT motif (TAAT), 40 bp upstream of 
the octamer motif (OCTA), was used to compare the binding of 
Oct-1 (A) and Oct-2 (B) in the absence and presence of VP16 as 
measured by protection from cleavage by DNase I. (- and +) 
Reactions contained combinations of E. coli-expressed Oct-1 or 
Oct-2 POU domain, affinity-purified HCF, and E. coli-expressed 
VP16 as indicated at the top of each lane. The direction and 
location of the sequences are indicated by arrows and brackets. 
(OCTA and TAAT) Probe contained wild-type octamer and 
(OCTA-)TAATGARAT sites; (TAAT) probe contained a wild- 
type (OCTA-)TAATGARAT site and amutant octamer motif; 
(OCTA) probe contained a wild-type octamer motif and a mu- 
tant (OCTA-)TAATGARAT site. Mutated sites are indicated 
by the XX's. The mutations were as shown in Fig. 1A. In this 
experiment, the sample in lane 9 was digested more extensively 
with DNase I than the other samples. 
tion of the (OCTA-)TAATGARAT site (lane 4). The ef- 
fects at the two different sites are independent of one 
another because the protection pattern of each site re- 
mains the same in the presence of the double point mu- 
tations (Fig. 1A) at the other site (lanes 7-12). The l imits 
of the (OCTA-)TA_ATGARAT site protection in the 
presence of VP16 are extended compared with the pro- 
tection by high concentrations of Oct-1 in the absence of 
VP16 (data not shown). This result indicates that VP16 is 
bound to the (OCTA-)TAATGARAT site, as described 
previously by Preston et al. (1988). Thus, it appears that 
Oct-1 and VP16 cooperate such that each binds more 
effectively over the (OCTA-)TAATGARAT site. We re- 
fer to this effect as corecruitment. 
In contrast o Oct-l, Oct-2 fails to respond to VP16, as 
shown in Figure 4B, because the (OCTA+)TAATGAR -
AT-like octamer protection pattern is not extended nor 
is the partial protection of the low-affinity (OCTA-)TA- 
ATGARAT site strengthened (lanes 2-4). Thus, core- 
cruitment o the (OCTA-)TAATGARAT site is selec- 
tive for VP16 and one (Oct-l), but not the other (Oct-2), 
of two proteins that display the same DNA-binding spec- 
ificity on their own. The recruitment of Oct-1 to the 
(OCTA-)TAATGARAT site in vitro supports the model 
that the VP16-dependent activation of the (OCTA-)TA- 
ATGARAT site in vivo involves an increase in Oct-1 
occupancy of this site, as suggested by the activation of 
the U2 promoter shown in Figure 3 in response to the 
carboxy-terminally truncated VP 16 protein (VP 16AC). 
Murine Oct-1 associates with VP16 less effectively 
than human Oct-1 
Because VP16 is not present in uninfected cells, it has 
been possible to determine the domains of the protein 
involved in VP16-induced transcriptional ctivation in 
vivo (Ace et al. 1988; Triezenberg et al. 1988a; Greaves 
and O'Hare 1989; Werstuck and Capone 1989a). In con- 
trast, it has not been possible to assess the relative abil- 
ities of or the activation domain requirements for Oct-1 
and Oct-2 to respond to VP16 in vivo, because Oct-1 is 
ubiquitously expressed and transient overexpression of
Oct-1 from the cloned eDNA in human cells does not 
enhance a response to VP16 (data not shown). To over- 
come this problem, we developed an in vivo assay for 
Oct-1 and Oct-2 response to VP16 in mouse cells. 
As shown in Figure 5A, the murine Oct-1 homeo do- 
main differs from that of human Oct-1 at four positions 
(Goldsborough et al. 1990; Stepchenko 1992). Two of 
these differences (E30D and M33L) are at positions that 
are important for association with VP16 (Stern et al. 
1989; Lai et al. 1992; Pomerantz et al. 1992). Consistent 
with this observation, Oct-1 in murine cell extracts does 
not associate with VP16 as effectively as does Oct-1 in 
human cell extracts (data not shown; H. Sch61er, pets. 
comm.), although such an effect could result from differ- 
ent levels of the stimulatory HCF protein in these ex- 
tracts. To compare directly the affinity of human and 
murine Oct-1 for VP16, we used in vitro-translated mu- 
rine and human Oct-1 in an electrophoretic mobil i ty re- 
tardation assay for VP16-induced complex formation on 
the (OCTA-)TAATGARAT site in the presence of a 
fixed level of human HCF. Figure 5B shows that in this 
assay, murine Oct-1 does form a VP16-induced complex 
(labeled VIC; cf. lanes 2 and 3 with lanes 4 and 5), but at 
a significantly reduced level from that of human Oct-1 
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Figure 5. Murine Oct-1 associates with VP16 less 
effectively than human Oct-1. (A) The positions and 
identities of Oct-1 amino acids that differ between 
the human and murine Oct-1 homeo domains are 
indicated on an illustration of the engrafted homeo 
domain bound to the major groove of DNA {stippled) 
[adapted from Kissinger et al. (1990)]. In the nomen- 
clature system used here, the identity of the human 
Oct-1 residue is given first in single-letter code, fol- 
lowed by its position in the homeo domain a d the 
identity of the differing murine Oct-1 residue. (B) 
Electrophoretic mobility retardation analysis com- 
paring VP16 association with murine Oct-1 and hu- 
man Oct-1. Either no in vitro translation extract {lane 1) or equivalent amounts of unpro- 
grammed (URL; lanes 2,3), or murine Oct-1 (lanes 4,5) or human Oct-1 (lanes 6, 7) programmed 
in vitro translation extracts were incubated with an (OCTA-)TAATGARAT probe in the ab- 
sence {-~ lanes 1,2,4,6) and presence (+; lanes 3,5,7) of E. coli-expressed VP16. All binding 
reactions contained partially purified human HCF. (VIC) VP16-induced complex. 
(lanes 6,7). Thus, murine Oct-1 has a lower affinity for 
VP16 than human Oct-l, most likely attributable to 
amino acid differences between the murine and human 
Oct-1 homeo domains. 
Oct-l, but not Oct-2 can activate transcription 
in vivo in response to VP16 
The lower affinity of murine Oct-1 for VP16 suggested 
that VP16 might not activate transcription as efficiently 
in mouse cells as in human cells, thus potentially pro- 
viding an in vivo assay for the response of human Oct-1 
and Oct-2 to VP16. We therefore tested the effects of 
VP16, human Oct-1 and Oct-2, as well as Oct-I/Oct-2 
chimeras and deletion mutants on transcription from 
our (OCTA-)TAATGARAT-containing f~-globin pro- 
moter construct in routine NIH-3T3 cells. The struc- 
tures of the Oct-related activators used in this assay are 
shown in Figure 6 (right}. The relative activities of each 
activator in the presence of VP16 (Activation) and the 
activators' relative levels of expression as determined by 
electrophoretic mobility retardation analysis of trans- 
fected cell extracts (Binding) are listed alongside the 
structures of the activators in Figure 6. Although the 
levels of Oct-related activator expression varied as much 
as 10-fold, this variation did not affect the discrimina- 
tion between Oct-1 and Oct-2 by VP16. The RNase pro- 
tection results in Figure 6 show that the (OCTA-)TAA- 
TGARAT site fails to respond to overexpression f Oct-1 
(Oct-l.l.1; lane 2) or Oct-2 (Oct-2.2.2; lane 5) in the ab- 
sence of VP16. In accord with the ability of VP16 to 
activate transcription i  another mouse cell line (Post et 
al. 1981; Triezenberg et al. 1988a, b) and the weak ability 
of murine Oct-1 to interact with VP16 (Fig. 5), the 
(OCTA-)TAATGARAT site is weakly active in the 
presence of VP16 (lane 3). Because we observe no pro- 
moter activity in the absence of VP16, on longer expo- 
sure of the autoradiograph, the activation by VP 16 alone 
can appear quite dramatic in mouse cells, with addi- 
tional human Oct-l, however, VP16 enhances the level 
of ~-globin mRNA expression 14-fold (of. lanes 3 and 4); 
as expected, this high level of activity is dependent on 
the wild-type (OCTA-)TAATGARAT site (lane 15). 
With additional human Oct-2, however, VP16 activation 
is not significantly enhanced (cf. lanes 3 and 6}. Thus, we 
have succeeded in developing a suitable assay to demon- 
strate in vivo that the (OCTA-)TAATGARAT site is 
Oct-1 but not Oct-2 responsive in the presence of VP16, 
probably because of selective VP16 and human Oct-1 
corecruitment to this otherwise unresponsive site. This 
effect results in differential transcriptional ctivation by 
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Figure 6. The Oct-1 POU domain is sufficient for VP16-induced positive control in vivo. The pU2/[3 reporter containing tandem 
wild-type (WT) or mutant [(Mut.) lane 15] (OCTA-)TAATGARAT (TAAT) sites was transfected into murine fibroblast NIH-3T3 cells 
together with expression vectors for Oct-1 or Oct-2, derivatives thereof, and/or VP16. The identity of the Oct-related activators i  
listed above each lane and the structure of each activator is shown diagrammatically at right. (-) No Oct-related activator was 
included. Lanes 16-19 are the result of a separate ransfection assay. In the right-hand panel, which shows the structures of the 
Oct-related activators, the hatched regions are derived from Oct-2. To the right of these stuctures i shown the quantitation of the 
activation in the presence of VP16 (Activation) and the expression of the Oct-related activators relative to Oct-1.1.1 {top) and POU-1 
(bottom), as determined by electrophoretic mobility retardation analysis (Binding) and normalized as described for reporter and effector 
expression, respectively, in Materials and methods. 
proteins with the same inherent DNA-binding specific- 
ity. 
The Oct-1 POU domain is sufficient for VP16-induced 
positive control 
We used the human Oct-l-dependent mouse cell assay 
for VP16-induced positive control of transcription to de- 
termine the sequences within Oct-1 that are required 
and sufficient for VP16-induced transcriptional activa- 
tion. In a matched pair of Oct-1 and Oct-2 chimeric pro- 
teins, in which the POU domains have been exchanged 
(Oct-2.1.2 and Oct-l.2.1; see Fig. 6, right, Tanaka and 
Herr 1990), the response to VP16 segregated with the 
Oct-1 POU domain (Fig. 6, left, lanes 7-10), consistent 
with the ability of these chimeras to associate with VP 16 
in vitro (Stern et al. 1989). Thus, Oct-2 sequences flank- 
ing the POU domain do not interfere with VP16-induced 
transcriptional activation in vivo. Furthermore, Oct-1 
mRNA promoter or snRNA promoter activation do- 
mains flanking the POU domain (Tanaka and Herr 1990; 
Tanaka et al. 1992) are not required for VP16 to activate 
transcription because when deleted, as in the Oct-1 POU 
domain construct Oct-A.1.A (lanes 11,12), a good re- 
sponse to VP16 remains. 
Consistent with in vitro complex assembly between 
Oct-1 and VP16 (Stem et al. 1989), the Oct-1 homeo do- 
main is apparently the key determinant for VP16-in- 
duced transcriptional positive control in vivo, because 
neither the Oct-2 POU domain (Oct-A.2.A; lanes 13,14) 
nor, in a separate assay, the Oct-1 POU domain carrying 
the Oct-2 homeo domain (cf. lanes 16 and 17 with lanes 
18 and 19) responds to VP16. This result also shows that 
the Oct-1 DNA-binding domain is sufficient for VP16- 
induced positive control, as if only the ability of Oct-1 to 
participate in corecruitment with VP16 is required to 
induce VP 16 to stimulate mRNA transcription from the 
(OCTA-)TAATGARAT site. 
Discuss ion  
Eukaryotic transcription factors are generally modular in 
structure, consisting of separable DNA-binding and tran- 
scriptional activation domains (Brent and Ptashne 1985; 
Ptashne 1988). Although the sequence specificity of 
DNA-binding domains is a major determinant for pro- 
moter selectivity in transcriptional regulation, DNA- 
binding alone falls short of explaining the ability of pro- 
teins with similar DNA-binding specificity to activate or 
repress different arget promoters. Homeo domain pro- 
teins are prime examples of proteins that share similar or 
identical DNA-binding specificities and yet effect differ- 
ent patterns of gene expression. One way to achieve such 
differential gene regulation is through the use of pro- 
moter-selective activation domains, which can discrim- 
inate between different promoters. In this way, Oct-1 
preferentially activates RNA polymerase II transcription 
from an snRNA promoter and Oct-2 preferentially acti- 
vates transcription from an mRNA promoter (Tanaka et 
al. 1992). Here, we have shown that like activation do- 
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mains, DNA-binding domains also can be used to 
achieve differential regulation by proteins that display 
the same DNA-binding specificity on their own. 
Role of DNA-binding domains m positive control 
In eukaryotes, there are now numerous examples of 
DNA-binding domain mutations that affect transcrip- 
tional regulation by transcription factors without obvi- 
ously affecting their DNA-binding ability, including mu- 
tations in the glucocorticoid receptor (Hollenberg and 
Evans 1988; Schena et al. 1989), the yeast activator 
HAP1 (Kim and Guarente 1989), and the muscle cell- 
specific transcription factors MyoD (Weintraub et al. 
1991; Davis and Weintraub 1992) and myogenin 
(Schwarz et al. 1992); the presumptive protein associa- 
tion affected by these mutations has not, however, been 
identified. In prokaryotes, the paradigm of this type of 
mutation is positive control mutations in the bacterio- 
phage ~ repressor. Such positive control mutations affect 
the ability of ~ repressor to stimulate transcription of its 
own gene without disrupting its ability to bind DNA or 
to act as a repressor (Guarente t al. 1982); they lie on the 
solvent-exposed surface of the DNA-bound ~ repressor 
DNA-binding domain, which consists of a helix-turn- 
helix motif similar in structure to the homeo domain 
(Hochschild et al. 1983). By replacing the Oct-1 homeo 
domain with the Oct-2 homeo domain, we have shown 
that mutations on the surface of the Oct-1 homeo do- 
main disrupt VP16-dependent transcriptional ctivation 
in vivo. Because of the strong parallels to X repressor, we 
refer to these mutations as positive control mutations. 
Their effects are better understood than those of other 
eukaryotic positive control mutations because both the 
structure of the homeo domain and the identity of the 
protein targeting the DNA-binding domain are known. 
Differential transcriptional regulation 
through selective corecruitment 
Previous studies have shown that by virtue of its potent 
acidic activation domain, VP16 causes Oct-1 to activate 
transcription of mRNA-type promoters in a manner 
more typical of Oct-2 (for review, see Herr 1992). Anal- 
ysis of Oct-1 and Oct-2 transcriptional ctivation from 
the (OCTA-)TAATGARAT site has shown that VP16 
and Oct-1 corecruitment can result in activation of a 
promoter that fails to respond to Oct-2. Corecruitment 
by DNA-binding transcriptional regulators has lso been 
observed with the yeast ranscription factors MCM1 and 
od (Bender and Sprague 1987) and al and cx2 (Dranginis 
1990). Here, corecruitment is used to bring Oct-1 but not 
Oct-2 to the (OCTA-)TAATGARAT site, thereby 
achieving differential regulation of transcription by pro- 
teins that display the same DNA-binding specificity on 
their own. Thus, Oct-2 can activate octamer motif-con- 
taming mRNA promoters through the use of promoter- 
selective activation domains, and Oct-1 can activate 
TAATGARAT-containing mRNA promoters through se- 
lective association with VP16. In this same manner, 
VP16 effectively expands the repertoire of Oct-l-respon- 
sive sites without affecting the number of Oct-2-respon- 
sive sites. 
The corecruitment by the ubiquitous cellular protein 
Oct-1 and the viral protein VP16 to the (OCTA-)TAAT- 
GARAT site leads to promoter activation by Oct-1 that 
is cell type specific in the sense that only HSV-infected 
cells or cells expressing VP 16 show transcriptional stim- 
ulation of (OCTA-)TAATGARAT. Such promoter se- 
lectivity by corecruitment between a broadly expressed 
homeo domain protein and a more narrowly expressed 
cofactor may also explain cell-specific transcriptional 
regulation by more broadly expressed homeo domain 
proteins during development as in Drosophila. 
We have shown that the Oct-1 DNA-binding domain, 
the POU domain, is sufficient both to achieve VP16 core- 
cruitment o the (OCTA-)TAATGARAT site in vitro 
and to effect VP16-induced positive control in vivo. 
Thus, when activating transcription i  association with 
VP16, the Oct-1 POU domain can be viewed as possess- 
ing inseparable DNA-binding and activation surfaces. 
The activation surface, or what might functionally be 
referred to as the activation domain, activates transcrip- 
tion by recruiting VP16 with its potent acidic activation 
domain to the c/s-regulatory target. Whereas differential 
promoter activation by Oct-1 and Oct-2 through pro- 
moter-selective activation domains probably involves 
"long-range" interactions with the promoter-proximal 
initiation complex, the second mechanism for differen- 
tial activation shown here probably involves "short- 
range" interactions with the Oct-1 DNA-binding do- 
main in which Oct-1 and VP16 come together to aug- 
ment each other's occupancy of the (OCTA-)TAATGA- 
RAT site. 
Implications of Oct-1 homeo domain variability 
in mice and humans 
The primary structure of the Oct-1 homeo domain is 
conserved among Xenopus (Smith and Old 1990), chick- 
ens (Petryniak et al. 1990), and humans (Sturm et al. 
1988)--members of three separate vertebrate classes. 
During mammalian evolution, however, the homeo do- 
main has varied. This variation can be seen when the 
human and rodent Oct-1 homeo domains are compared. 
As illustrated in Figure 5, the murine Oct-1 homeo do- 
main contains four differences with respect to its human 
counterpart (Goldsborough et al. 1990; Stepchenko 
1992). Even within rodents the Oct-1 homeo domain var- 
ies because a partial rat Oct-1 homeo domain sequence 
shows that this homeo domain contains the same four 
murine differences and, in addition, a pair of differences 
at the amino-terminal end of helix 1 (Lillycrop and 
Latchman 1991). Curiously, two of the rodent-specific 
differences in helix 2 (M33L and D36E) are identical to 
the residues found at these positions in murine (Hatzo- 
poulous et al. 1990) and human (Clerc et al. 1988; Ko et 
al. 1988; Mfiller et al. 1988; Scheidereit et al. 1988) Oct- 
2; perhaps the changes in the murine Oct-1 homeo do- 
main arose in part by gene conversion with the Oct-2- 
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coding sequences. The methionine to leucine exchange 
at position 33 (M33L) is partially responsible for the poor 
association of VP16 with Oct-2 (Stern et al. 1989; Lai et 
al. 1992; Pomerantz et al. 1992), whereas the glutamic 
acid residue at position 30 of the human Oct-1 homeo 
domain is also important for association with VP16 (Pom- 
erantz et al. 1992). It is therefore likely that the murine 
Oct-1 M33L and E30D glutamate-to-aspartate changes 
are responsible for the weakened association of murine 
Oct-1 with VP16. 
The weaker association of murine Oct-1 and VP 16 led 
to the development of an in vivo assay for the involve- 
ment of Oct-1 in the activation of transcription by VP 16. 
The success of this assay was unexpected because the 
original finding that a virion component, which was later 
identified as VP16 (Campbell et al. 1984), trans-activates 
the HSV immediate arly promoters was made in mouse L 
cells (Post et al. 1981). Our studies show that VP16 does 
activate transcription in murine cells (see Fig. 6); and be- 
cause the background transcription level in the absence of 
VP16 is undetectable, the fold activation by VP16 in mu- 
rme cells appears very large. Only when contrasted with 
the enhanced level of VP16 activation in the presence of 
transiently expressed human Oct- 1 does the VP 16 response 
with endogenous murine Oct-1 appear weak. 
The variability exhibited by rodent Oct-1 homeo do- 
mains has implications for the involvement of the Oct-1 
homeo domain in the regulation of cellular gene tran- 
scription through protein-protein interactions with its 
solvent-exposed surface. An attractive hypothesis to ex- 
plain how Oct-1 may mediate activation of cellular 
mRNA-type promoters has been that cellular cofactors 
exist that, like VP16, interact with the Oct-1 homeo do- 
main to regulate transcription. But the evolutionary di- 
versity of the Oct-1 surface that directs association with 
VP16, together with its apparent deleterious effects on 
VP16-induced positive control, suggests that the varia- 
tion in the murine Oct-1 homeo domain would have an 
impact on the association of Oct-1 and such a cellular 
cofactor unless perhaps (1) the cellular cofactor interacts 
with a different--unaffected--surface of the Oct-1 ho- 
meo domain or (2) the cellular cofactor has effectively 
evolved to compensate for the changes in the rodent 
Oct-1 homeo domains. Alternatively, a weakened cofac- 
tor/Oct-1 interaction is still sufficient for activity or the 
activity is no longer required, perhaps because a separate 
mechanism evolved in rodents that circumvents the re- 
quirement for positive control by the Oct-1 homeo do- 
main and therefore for an Oct-1 homeo domain cofactor. 
In addition to its evolutionary implications, the poorer 
ability of mouse Oct-1 to associate with VP16 compared 
with human Oct-1 has implications for the use of ro- 
dents as animal models for HSV infection. The difference 
in an important virus-host cell interaction for activation 
of the HSV immediate early genes suggests that the 
course of HSV infection in mice or rats, particularly the 
balance between latent and lytic infection, may differ 
from that in humans. It may be possible to evaluate the 
influence of human Oct-1 on the pathology of HSV in- 
fection by using mice expressing human Oct-1. 
Materials and methods  
Construction of reporter plasmids 
The pU2/[3 plasmid contains a U2 promoter-driven transcrip- 
tion unit, the HindIII fragment from pU2/-  198 (Hernandez and 
Lucito 1988), inserted into the SstI site of the [3-globin pro- 
moter-containing plasmid p~A 36 (Tanaka and Herr 1990). Six- 
tandem-copy cis-regulatory elements were generated by succes- 
sive ligation of the individual 24-bp double-stranded DNA ele- 
ments made with complementary s nthetic oligonucleotides 
and then inserted into the SphI site in the plasmid ppe- as 
described (Ondek et al. 1988). To transfer these tandem-copy 
segments to the pU2/p plasmid, they were excised from the 
ppe- derivative by PstI-HindIII digestion and inserted blunt- 
ended into the SmaI site of the pUC119 polylinker sequence in 
pU2/p between the p-globin and U2 promoters. The four new 
six-tandem-copy elements described here (Fig. 1A) are referred 
to as pU2/p6 x H2B/OCTA for the human H2B-derived oc- 
tamer element (LaBella et al. 1988) and pU2/p6 x H2B/ 
OCTAdpm 1for the corresponding mutant site, and pU2/p6 x 
ICP4/TAAT-1 for the (OCTA-)TAATGARAT site (Preston et 
al. 1988) and pU2/p6 x ICP4/TAAT-ldpm 1 for the correspond- 
ing mutant site. The six-tandem octa + sph + and octa-sph- el- 
ements were transferred from p[36 x B20 and p[36 x B20 dpm8, 
respectively (Tanaka et al. 1988). Except for the wild-type and 
mutant (OCTA-)TAATGARAT elements, each site was in the 
plus (+) orientation, meaning that the sequence in Figure 1A 
reads 5' to 3' in a clockwise direction in Figure lB. The 
(OCTA-)TAATGARAT elements, which function in either ori- 
entation, were placed in the opposite minus (-)  orientation 
because this direction provides the best similarity to the oc- 
tamer motif as described in Baumruker et al. (1988). The inter- 
nal reference plasmid p~4 x (A+C) containing the human 
~-globin transcription unit is described in Tanaka and Herr 
(1990). 
Effector plasmids 
Expression constructs for wild-type Oct-1 (pCGoct-l.l.1) and 
Oct-2 (pCGoct-2.2.2), the Oct- 1/Oct-2 chimeras pCGoct- 1.2.1 
and pCGoct-2.1.2, and the Oct-1 and Oct-2 deletion constructs 
pCGoct-A.1.A and pCGoct-A.2.A, are described in Tanaka and 
Herr (1990). POU- 1 (pCGoct- 1-POU) and POU- 1 (Ho2) [pCGoct- 
1-POU(Ho2)] are described in Lai et al. (1992). The expression 
constructs for wild-type VP 16 (pCGNVP 16), carboxy-terminally 
truncated VP 16AC (pCGNVP 16AC; containing residues 5-410), 
and the inl4 insertion mutant (Ace et al. 1988) in the VP16AC 
background (pCGNVP16AC-inl4) contain the VP16-coding se- 
quences inserted between the pCG (Tanaka nd Herr 1990) XbaI 
and BamHI sites (A. Wilson and W. Herr, unpubl.). 
In vivo transcription assays 
HeLa cells were seeded at 5 x l0 s cells per 10-cm plate and 
transfected after 24 hr by calcium phosphate coprecipitation as 
described by Tanaka et al. (1988). Each reporter construct (4 ~g) 
was transfected along with the internal reference plasmid 
pc~4 x (A + C) (68 ng). In those cells where wild-type or mutant 
VP16 proteins were coexpressed, 1 ~g of pCGNVP16 or a deriv- 
ative was cotransfected. NS-1 cells, a nonsecreting mouse my- 
eloma cell line, were transfected by the DEAE-dextran and 
chloroquine method as described by Ondek et al. (1987). Cells 
(1 x 10 z) on 10-cm plates were transfected with 4 ~g of pU2/p 
reporter plasmid and 1 ~g of pc,4 x (A+ C). Murine NIH-3T3 
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fibroblasts were seeded at 3.5 x l0 s cells per 10-cm plate 24 hr 
in advance and transfected in the manner described for HeLa 
cells except hat 0.46 ~g of each plasmid expressing Oct-l, Oct- 
2, or Oct-1 and Oct-2 variants and 0.54 Ixg of pCGNVP16 were 
cotransfected where appropriate. 
To measure xpression of Oct-l, Oct-2, and VPl6-related pro- 
teins in HeLa or NIH-3T3 cells, cell extracts were prepared from 
one-tenth of the harvested cells and assayed by mobility retar- 
dation analysis as described (Tanaka et al. 1992) using a single- 
copy (OCTA-)TAATGARAT probe. Endogenous HCF is not 
effectively extracted under the experimental conditions de- 
scribed in Tanaka et al. (1992); therefore, to measure VP16 ex- 
pression, the binding reactions were supplemented with par- 
tially purified HCF {see below). Expression of the VP16-related 
proteins was also assayed by performance of an alkaline 
phophatase immunoblot analysis (as described in Harlow and 
Lane 1988) with the VP16-specific monoclonal antibody LP1 
(McLean et al. 1982) as the primary antibody. 
To measure reporter gene expression, cytoplasmic RNA was 
collected by the NP-40/lysis method and analyzed by RNase 
protection (Ondek et al. 1987). The probes used for RNA hy- 
bridization were antisense transcripts to a-globin mRNA (~98; 
Gilman 1988), 13-globin mRNA ([5134; W. Thomann and W. 
Herr, unpubl.), or the U2 promoter-driven s RNA transcription 
construct (Probe A; Hernandez and Lucito 1988). Unprotected 
RNA was digested by RNases A and T1, and the protected frag- 
ments were visualized after electrophoresis through a 6% dena- 
turing gel. Levels of reporter and effector gene expression were 
quantitated with a Fuji BAS2000 PhosphorImager and normal- 
ized to the level of expression of the internal reference a-globin 
RNA. For the NIH-3T3 cell assay shown in Figure 6, the inter- 
nal c~-globin reference varied from 23% to 100% of the highest 
level before normalization. 
HCF purification 
HCF activity was purified from HeLa cells by protein affinity 
with VP16 (Kristie and Sharp 1990; Xiao and Capone 1990; 
Stern and Herr 1991). Protein A-VP16 fusion protein prepared 
from 2 liters of E. coli and purified over IgG-Sepharose as de- 
scribed previously (Stern and Herr 1991) was rebound to 500 ~1 
of IgG--Sepharose in a 1-ml disposable pipette. After equilibra- 
tion with buffer D, 5 ml of nuclear extract (Dignam et al. 1983} 
was passed over the protein A-VP 16 column. The column was 
subsequently washed with 5 ml of TST buffer and eluted with 1 
M KC1 as described previously for the HCF microprecipitation 
assay (Xiao and Capone 1990; Stern and Herr 1991). Peak activ- 
ity fractions were screened by mobility retardation assay with E. 
coli-expressed Oct-1 POU domain and protein A-VP16 fusion 
protein, pooled, and dialyzed against 0.1 M KC1, 50 mM Tris (pH 
7.6) and 20% sucrose. This HCF preparation was devoid of de- 
tectable Oct-1 as determined by mobility retardation analysis. 
DNase I protection analysis 
To generate the probes used for DNase I protection, one copy of 
a flush-end XhoI fragment with the wild-type or mutant H2B 
octamer sequence (Fig. 1A) was cloned into the HindIII site of 
the pUC119 polylinker and an analogous copy of the wild-type 
or mutant (OCTA-)TAATGARAT sequence (Fig. 1A) was 
cloned into the HincII site of the pUC119 polylinker. The oc- 
tamer- and (OCTA-)TAATGARAT-containing vector was then 
digested with EcoRI and the ends were filled in by the Klenow 
fragment and radiolabeled dATP and dTTP, followed by diges- 
tion with BstNI and polyacrylamide gel purification. For each 
DNase I protection, 20,000 cpm of probe was used. Protein- 
DNA-binding reactions were performed in 12.5-1zl reactions 
containing 8 mM Na-HEPES (pH 7.9), 60 mM NaC1, 4 mM sper- 
midine, 2 mM EDTA, 0.2 mM DTT, 0.03% NP-40, 0.1 mg/ml of 
BSA, 0.01 mg/ml of unsonicated poly[d(I-C)] (Pharmacia), and 
2% polyvinyl alcohol. E. coli-expressed Oct-1 and Oct-2 POU 
domain protein (-0.24 ng per reaction) purified to near homo- 
geneity (>90%) by DNA affinity {Kadonaga nd Tjian 1986) was 
used. Where appropriate, 1 txl of partially purified HCF and -25 
ng of protein A-VP16 were used. 
For DNase I protection analysis, the protein-DNA-binding 
reactions were incubated at 37~ for 30 min and then on ice 
until treatment. Before the addition of DNase I, 50 ~1 of ice-cold 
10 mM MgC1J5 mM CaC12 was added to the reactions, which 
were then incubated on ice for 1 min. DNase I (100 ng) was then 
added; and after a 1-min incubation on ice, the cleavage reac- 
tions were stopped by the addition of 90 txl of 20 mM EDTA (pH 
8), 1% SDS, 0.2 M NaC1, and 100 ~g of yeast RNA. Samples were 
phenol extracted once, ethanol precipitated, and analyzed by 
6% denaturing polyacrylamide g l electrophoresis. 
Mobility retardation analysis 
In vitro-translated murine Oct-1 and human Oct-1 were gener- 
ated by the use of plasmids oct-1 clone 8 (gift of H. Sch61er; 
Sch61er et al. 1990) and pBSoct-1 + (Sturm et al. 1988), respec- 
tively. Each coding sequence was rendered transcribable by SP6 
polymerase through polymerase chain reaction (PCR) amplifi- 
cation with an Oct-l-related primer containing the SP6 pro- 
moter and a primer complementary to pUG119 polylinker se- 
quence as described previously (Aurora and Herr 1992). Oct-l- 
encoding SP6 transcripts were then translated in vitro by use of 
a rabbit reticulocyte lysate. Levels of the [3SS]methionine- la- 
beled in vitro translation products were measured after fraction- 
ation of the products on a polyacrylamide g l. Translation ex- 
tracts were equilibrated for Oct-1 expression with unpro- 
grammed reticulocyte lysate, and 3 ~1 was used in mobility 
retardation analysis as follows. Binding reactions were carried 
out in 10-~1 volumes in 4 mM Tris-HC1 (pH 7.9), 20 mM KC1, 1.4 
mM DTT, 0.4 mM EDTA, 0.04% NP-40, 0.4 % glycerol, and 
0.8% Ficoll with 1 ng of denatured salmon sperm DNA, 1 ~g of 
poly[d(I-C)], 0.5 vl of partially purified HCF. Where appropriate, 
40 ng of glutathion S-transferase (GST)-VP16AC fusion protein 
was included in the reactions. The HCF and GST-VP16AC prep- 
arations were a gift of A. Wilson (Cold Spring Harbor Labora- 
tory). Binding was carried out at 30~ for 30 min before samples 
were loaded on a 4% 1 : 39 bis/acrylamide gel prepared in 20 
mM Tris, 0.2 M glycine, and 1 mM EDTA and subjected to elec- 
trophoresis. 
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